We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Two Newly Developed Tests May Better Diabetes Diagnosis and Monitoring

By LabMedica International staff writers
Posted on 28 Jul 2015
At AACC 2015 (July 26-30; Atlanta, GA, USA) research teams presented results of successful testing of two new potential methods for diagnosing and monitoring diabetes in its standard or gestational forms. The findings may lead to easier, timelier, and more affordable ways of identifying and treating this chronic disease.

One test study, by a research team led by Prof. Sridevi Devaraj, PhD, of Texas Children’s Hospital and Baylor College of Medicine (Houston, TX, USA), was to determine if a blood biomarker could be identified for gestational diabetes (GD), which occurs only during pregnancy and poses serious health risks for both mother and baby.

Today’s test for standard diabetes, which measures levels of the biomarker glycated hemoglobin (HbA1c), has limited usefulness for GD. The HbA1c test measures patient average glucose blood levels over a period of 3 months, and cannot be used to determine a patient’s blood glucose values on a daily, or even weekly, basis. This makes it challenging to closely track glucose levels during relatively few weeks of pregnancy, especially as GD is not diagnosed until the 3rd trimester.

Using stored blood samples collected from 124 pregnant women, Prof. Devaraj and her colleagues measured the levels of 3 types of proteins. They found that the levels of one—1,5Anhydroglucitol (1,5AG)—were significantly different in the women diagnosed with GD. The researchers were also able to establish a specific cutoff level at which the concentration of 1,5AG became a reliable predictor of which women had diabetes. One of the main potential advantages of 1,5AG as a biomarker for GD is its short “halflife” of 2 weeks, compared to HbA1c’s of 3 months.

“Our findings are very preliminary and need to be confirmed in larger groups of women,” said Prof. Devaraj, “but, if confirmed, they suggest a possible new and more immediate approach for diagnosing and monitoring diabetes during pregnancy.”

For the second test study, a research team led by Joris R. Delanghe, MD, PhD, Ghent University (Ghent, Belgium), investigated the novel view of whether fingernail clippings could be used instead of blood to diagnose and monitor diabetes. They collected nail clippings from 25 people with and 25 without diabetes. After the clippings were ground into powder, a relatively inexpensive spectrometer was used to measure the amount of nail protein that had undergone glycation (bonding with sugar molecules).

“We found a striking difference in the measurements between the control group and the patients with diabetes,” said Prof. Delanghe, “This finding suggests that nail clippings may serve as a reliable and noninvasive diagnostic tool,” with potential to make diagnosing diabetes much simpler and less expensive. Nail clippings, unlike blood samples, can be obtained noninvasively. They also take up little space and can be stored at room temperature for at least 1 month without affecting spectrometer outcomes.

“The proposed test may become particularly useful in low and middle income countries, where laboratories are often located long distances from where patients live,” said Prof. Delanghe.

Related Links:

American Association for Clinical Chemistry (AACC)
AACC 2015 Annual Meeting & Clinical Lab Expo

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Drug Testing Assays
Atellica DT 250 Analyzer
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test

Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more